Searching for new avenues to differentiate its diabetes offerings, Sanofi has entered into an alliance with artificial intelligence (AI) specialist, Exscientia, to develop bispecific small molecules. Centered on metabolic diseases - primarily diabetes and its associated conditions - the deal involves drug design and development with Exscientia’s AI-based platform and chemical synthesis assistance from Sanofi. Any licensed products that reach the market will qualify for milestone payments up to €250 M (US$274 M).